NASDAQ · MYGN
Healthcare · Medical - Diagnostics & Research
$4.01
Down-$0.04 (-1.00%)
Updated Sep 22, 2026, 3:02 PM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
MYGN closed at $4.01 after 20 trading sessions, up 31.48% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 21, 2026 | $3.93 | $4.035 | $3.87 | $4.01 | 1.89M |
| Sep 18, 2026 | $4.15 | $4.17 | $3.86 | $3.89 | 3.51M |
| Sep 17, 2026 | $3.885 | $4.17 | $3.75 | $4.14 | 2.83M |
| Sep 16, 2026 | $3.75 | $4.085 | $3.75 | $3.86 | 2.05M |
| Sep 15, 2026 | $3.795 | $3.98 | $3.695 | $3.88 | 4.68M |
| Sep 14, 2026 | $3.43 | $3.82 | $3.42 | $3.79 | 2.6M |
| Sep 11, 2026 | $3.37 | $3.425 | $3.195 | $3.42 | 2.55M |
| Sep 10, 2026 | $3.14 | $3.365 | $3.06 | $3.36 | 3.94M |
| Sep 9, 2026 | $3.11 | $3.215 | $3.085 | $3.19 | 967K |
| Sep 8, 2026 | $3.18 | $3.215 | $3.105 | $3.18 | 1.19M |
| Sep 4, 2026 | $3.19 | $3.20 | $3.15 | $3.19 | 806.16K |
| Sep 3, 2026 | $3.25 | $3.32 | $3.16 | $3.23 | 959.06K |
| Sep 2, 2026 | $3.16 | $3.35 | $3.16 | $3.23 | 1.35M |
| Sep 1, 2026 | $2.95 | $3.215 | $2.92 | $3.18 | 3.03M |
| Aug 31, 2026 | $3.15 | $3.26 | $3.04 | $3.22 | 1.54M |
| Aug 28, 2026 | $3.15 | $3.20 | $3.07 | $3.16 | 1.43M |
| Aug 27, 2026 | $3.11 | $3.2699 | $3.09 | $3.18 | 1.28M |
| Aug 26, 2026 | $3.18 | $3.19 | $3.085 | $3.12 | 1.29M |
| Aug 25, 2026 | $3.06 | $3.21 | $3.01 | $3.19 | 1.76M |
| Aug 24, 2026 | $3.20 | $3.20 | $3.00 | $3.05 | 1.35M |
The latest Smart Investors Daily articles mentioning MYGN.
MYGN research
Company profile and research snapshot.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | UBS | Neutral | — |
| Sep 1, 2026 | Piper Sandler | Underweight | — |
| Aug 18, 2026 | Stephens & Co. | Equal-Weight | — |
| Aug 3, 2026 | Wells Fargo | Equal-Weight | — |
| Jul 31, 2026 | TD Cowen | Hold | — |
No generated briefing is available yet.
Benzinga · Sep 16, 2026
Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $770.000 million-$790.000 million to $770.000 million-$790.000 million vs $776.790 million estimate.
Benzinga · Sep 9, 2026
UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price target from $6 to $3.6.
Yahoo · Sep 8, 2026
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers.
Yahoo · Sep 4, 2026
Adma Biologics (ADMA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MYGN.
